Sutro Biopharma Asset Resilience Ratio
Sutro Biopharma asset resilience ratio. Sutro Biopharma (STRO) has an Asset Resilience Ratio of 56.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Sutro Biopharma fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sutro Biopharma (2016–2025)
Asset resilience ratio of Sutro Biopharma from 2016 to 2025. This chart shows how Sutro Biopharma's Asset Resilience Ratio has changed over time. Read Sutro Biopharma debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sutro Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see STRO asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $110.01 Million | 56.57% |
| Total Liquid Assets | $110.01 Million | 56.57% |
Asset Resilience Insights
- Very High Liquidity: Sutro Biopharma maintains exceptional liquid asset reserves at 56.57% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sutro Biopharma Industry Peers by Asset Resilience Ratio
Compare Sutro Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Sutro Biopharma Asset Resilience Ratio by Year (2016–2025)
Sutro Biopharma asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Sutro Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 47.92% | $83.30 Million | $173.83 Million | +15.23pp |
| 2024-12-31 | 32.69% | $126.59 Million | $387.21 Million | -32.39pp |
| 2023-12-31 | 65.08% | $306.35 Million | $470.74 Million | -5.47pp |
| 2022-12-31 | 70.55% | $287.11 Million | $406.94 Million | +21.48pp |
| 2021-12-31 | 49.07% | $167.52 Million | $341.41 Million | +7.97pp |
| 2020-12-31 | 41.10% | $161.99 Million | $394.11 Million | -31.10pp |
| 2019-12-31 | 72.20% | $112.90 Million | $156.37 Million | +36.71pp |
| 2018-12-31 | 35.49% | $79.19 Million | $223.14 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $40.77 Million | -- |
| 2016-12-31 | 51.86% | $35.93 Million | $69.28 Million | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid… Read more